Back to search

Switzerland· 68388002

Trixeo Aerosphere 5/7.2/160 μg, Druckgasinhalation, Suspension

A formoterol, glycopyrronium bromid und budesonid product containing budesonidum, glycopyrronium, formoteroli fumaras dihydricus, registered in Switzerland by AstraZeneca AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC R03AL11

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTrixeo Aerosphere 5/7.2/160 μg, Druck…ATCR03AL11REGISTER NO.68388002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Formoterol, glycopyrronium bromid und budesonid is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AL11 (formoterol, glycopyrronium bromid und budesonid), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Formoterol, glycopyrronium bromid und budesonid · ATC R03AL11

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
budesonidum, glycopyrronium, formoteroli fumaras dihydricus
Manufacturer
AstraZeneca AG
Country
Switzerland (CH)
ATC code
R03AL11
ATC class
Formoterol, Glycopyrronium bromid und Budesonid
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680683880026
    120 Dos
    CHF 74.15

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c301590b-054b-45db-9d8b-e2fdd8739439
GET /v1/drugs/c301590b-054b-45db-9d8b-e2fdd8739439?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "formoteroli fumaras dihydricus 5 mcg + glycopyrronium 7.2 mcg + budesonidum 160 mcg",
  "valid_from": "2022-06-01",
  "limitations": "[{\"description\":\"Für Patienten mit moderater COPD nach ≥ 1 moderaten Exazerbation pro Jahr trotz einer mindestens 3 Monate dauernder optimierter Therapie unter LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/μl, welche nicht ausreichend eingestellt sind<br>\\noder<br>\\nfür Patienten mit moderater bis schwerer COPD nach ≥ 2 moderaten Exazerbationen pro Jahr oder ≥ 1 Exazerbation pro Jahr, welche zu einer Hospitalisation geführt hat trotz einer mindestens 3 Monaten dauernden optimierter Therapie unter ICS/LABA oder LABA/LAMA (für LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/μl), welche nicht ausreichend eingestellt sind<br>\\noder<br>\\nfür Patienten mit COPD, welche bereits mit einer Dreifach-Kombination bestehend aus LABA, ICS und LAMA mit einem oder mehreren Inhalatoren therapiert werden.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2022-06-01\"}]",
  "galenic_form": "Inhalator 5/7.2/160 mcg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-06-01",
  "self_retention_pct": 10
}

See everything about formoterol, glycopyrronium bromid und budesonid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.